|
KMID : 1188320100040030357
|
|
Gut and Liver
2010 Volume.4 No. 3 p.357 ~ p.362
|
|
|
Efficacy of Rifaximin Compared with Ciprofloxacin for the Treatment of Acute Infectious Diarrhea: A Randomized Controlled Multicenter Study
|
|
Hong Kyoung-Sup
Kim You-Sun
Han Dong-Soo
Choi Chang-Hwan
Jang Byung-Ik
Park Young-Sook
Lee Kang-Moon
Lee Soo-Teik
Kim Hyun-Sook
Kim Joo-Sung
|
|
|
Abstract
|
|
|
Background/Aims: Ciprofloxacin has been widely prescribed for acute infectious diarrhea. However, the resistance to this drug is increasing. Rifaximin is a novel but poorly absorbed rifamycin derivative. This study evaluated and compared the efficacies of rifaximin and ciprofloxacin for the treatment of acute infectious diarrhea.
Methods: We performed a randomized controlled multicenter study in Korea. Patients with acute diarrhea were enrolled and randomized to receive rifaximin or ciprofloxacin for 3 days. The primary efficacy endpoint was the time to last unformed stool (TLUS). Secondary endpoints were enteric wellness (reduction of at least 50% in the number of unformed stools during 24-hour postenrollment intervals), general wellness (subjective feeling of improvement), and proportion of patients with treatment failure.
Results: Intent-to-treat analysis (n=143) showed no significant difference between the rifaximin and ciprofloxacin groups in the mean TLUS (36.1 hours vs 43.6 hours, p=0.163), enteric wellness (49% vs 57%, p=0.428), general wellness (67% vs 78%, p=0.189), or treatment failure rate (9% vs 12%, p=0.841). The adverse events did not differ significantly between the two groups.
Conclusions: These results suggest that rifaximin is as safe and effective as ciprofloxacin in the treatment of acute infectious diarrhea.
|
|
|
KEYWORD
|
|
|
Acute infectious diarrhea, Rifaximin, Ciprofloxacin
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|